Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572872 | 0.83 | PTGS2 (0.32) | KMT2ABCHEACHESMN1; SMN2LMNA | |
| SCHEMBL19277947 | 0.75 | — | — | |
| SCHEMBL7776081 | 0.75 | — | — | |
| SCHEMBL7776631 | 0.74 | MEN1 (0.30) | KMT2AALDH1A1 | |
| SCHEMBL7776052 | 0.74 | — | — | |
| SCHEMBL19277430 | 0.69 | — | — | |
| SCHEMBL417350 | 0.69 | OAT (0.37) | KMT2ALMNATSHRKDM4E | |
| SCHEMBL19277433 | 0.69 | — | — | |
| SCHEMBL22563074 | 0.65 | CTSK (0.32) | HTT | |
| SCHEMBL5573120 | 0.65 | PTGS2 (0.32) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283342-A1 | ORGANIC COMPOUNDS | Givaudan, S.A. (CH) | 2017-10-05 | — | — | US | claimed |
| EP-3060535-B1 | PROCESS FOR THE CYCLOPROPANATION OF OLEFINS USING N-ALKYL-N-NITROSO COMPOUNDS | GIVAUDAN SA (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20170283342-A1 | ORGANIC COMPOUNDS | Givaudan, S.A. (CH) | 2017-10-05 | — | — | US | disclosed |
| US-9718741-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283342-A1 | ORGANIC COMPOUNDS | NOC2L, NOS2, NCL | KMT2A 912/4885BCHE 4256/4885ACHE 3514/4885 |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOC2L, NPM1, NOS2 | KMT2A 1178/4885BCHE 3763/4885ACHE 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.